Skip to main content
Top
Published in: Virchows Archiv 2/2004

01-02-2004 | Original Article

Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture

Authors: Edson Mantovani Barbosa, Sueli Nonogaki, Maria Lucia Hirata Katayama, Maria Aparecida Azevedo Koike Folgueira, Venâncio Ferreira Avancini Alves, Maria Mitzi Brentani

Published in: Virchows Archiv | Issue 2/2004

Login to get access

Abstract

Urokinase plasminogen activator (uPA), its cell-bound receptor (uPAR) and its main inhibitor plasminogen activator type 1 (PAI-1) are present primarily in stromal cells in invasive breast carcinoma. The purpose of this study was to investigate the regulation by 1,25 dihydroxyvitamin-D3 (VD3) of these invasion-associated markers expressed in breast cancer tumors under organ culture, which preserves the interacting network of tumor and stromal cells. Breast carcinoma slices (30 cases), obtained using the Krumdieck tissue slicer, cultured for 48 h in the presence or absence of 100 nM vitamin D3, were embedded in formalin-fixed paraffin. uPA, uPAR, PAI-1 and VD3 receptor (VDR) were analyzed by immunohistochemistry, and their expression, detected in tumor cells and fibroblasts of the specimens, was not statistically changed by culture conditions. The proportion of cases expressing uPA, uPAR and PAI-1 was not affected by VD3 in epithelial cells, but the fraction of cases displaying strong PAI-1 reactivity in fibroblasts was reduced (P=0.016) compared with control slices. Fibroblasts isolated from invasive ductal carcinomas and from normal breast tissues expressed higher VDR mRNA levels than epithelial cells. In cultured tumor fibroblasts, PAI-1 immunostaining and mRNA levels were reduced by VD3-limiting fibroblast contribution to invasion.
Literature
1.
go back to reference Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Dano K (1986) Plasminogen activator inhibitor type-I: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 209:213–218CrossRefPubMed Andreasen PA, Riccio A, Welinder KG, Douglas R, Sartorio R, Nielsen LS, Oppenheimer C, Blasi F, Dano K (1986) Plasminogen activator inhibitor type-I: reactive center and amino-terminal heterogeneity determined by protein and cDNA sequencing. FEBS Lett 209:213–218CrossRefPubMed
2.
go back to reference Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1–22PubMed Andreasen PA, Kjøller L, Christensen L, Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72:1–22PubMed
3.
go back to reference Arnheim N (1979) Characterization of mouse ribosomal gene fragments purified by molecular cloning. Gene 7:83–96CrossRefPubMed Arnheim N (1979) Characterization of mouse ribosomal gene fragments purified by molecular cloning. Gene 7:83–96CrossRefPubMed
4.
go back to reference Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 14:923–928 Bajou K, Noël A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 14:923–928
5.
go back to reference Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD, Hsieh JT (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Urol Oncol 21:314–315CrossRef Beer TM, Eilers KM, Garzotto M, Egorin MJ, Lowe BA, Henner WD, Hsieh JT (2003) Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer. Urol Oncol 21:314–315CrossRef
6.
go back to reference Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51:239–244PubMed Berger U, McClelland RA, Wilson P, Greene GL, Haussler MR, Pike JW, Colston K, Easton D, Coombes RC (1991) Immunocytochemical determination of estrogen receptor, progesterone receptor, and 1,25-dihydroxyvitamin D3 receptor in breast cancer and relationship to prognosis. Cancer Res 51:239–244PubMed
7.
go back to reference Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60:597–603PubMed Bianchi E, Cohen RL, Dai A, Thor AT, Shuman MA, Smith HS (1995) Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer 60:597–603PubMed
8.
go back to reference Christensen L, Simonsen ACW, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA (1996) Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66:441–452CrossRefPubMed Christensen L, Simonsen ACW, Heegaard CW, Moestrup SK, Andersen JA, Andreasen PA (1996) Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66:441–452CrossRefPubMed
9.
go back to reference Clemens TL, Garrett KP, Zhou X-Y, Pike JW, Haussler MR, Dempster DW (1988) Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 122:1224–1230PubMed Clemens TL, Garrett KP, Zhou X-Y, Pike JW, Haussler MR, Dempster DW (1988) Immunocytochemical localization of the 1,25-dihydroxyvitamin D3 receptor in target cells. Endocrinology 122:1224–1230PubMed
10.
go back to reference Colston KW, Hansen CM (2002) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45–59PubMed Colston KW, Hansen CM (2002) Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9:45–59PubMed
11.
go back to reference Constantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77:1079–1088CrossRefPubMed Constantini V, Sidoni A, Deveglia R, Cazzato OA, Bellezza G, Ferri I, Bucciarelli E, Nenci GG (1996) Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression. Cancer 77:1079–1088CrossRefPubMed
12.
go back to reference Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563–1571PubMed Deng G, Curriden SA, Wang S, Rosenberg S, Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release? J Cell Biol 134:1563–1571PubMed
13.
go back to reference Dublin E, Hanby A, Patel NK, Liebman R, Barnes D (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am J Pathol 157:1219–1227PubMed Dublin E, Hanby A, Patel NK, Liebman R, Barnes D (2000) Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Am J Pathol 157:1219–1227PubMed
14.
go back to reference El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R (2000) The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60:4412–4418PubMed El Abdaimi K, Dion N, Papavasiliou V, Cardinal PE, Binderup L, Goltzman D, Ste-Marie LG, Kremer R (2000) The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Res 60:4412–4418PubMed
15.
go back to reference Escaleira MTF, Brentani MM (1999) Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat 54:123–133CrossRefPubMed Escaleira MTF, Brentani MM (1999) Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res Treat 54:123–133CrossRefPubMed
16.
go back to reference Faraco JH, Morrison NA, Baker A, Shine J, Frossard PM (1989) ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res 17:2150PubMed Faraco JH, Morrison NA, Baker A, Shine J, Frossard PM (1989) ApaI dimorphism at the human vitamin D receptor gene locus. Nucleic Acids Res 17:2150PubMed
17.
go back to reference Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J. Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma (1998) J Histochem Cytochem 46:1335–1337PubMed Friedrich M, Rafi L, Tilgen W, Schmidt W, Reichrath J. Expression of 1,25-dihydroxy vitamin D3 receptor in breast carcinoma (1998) J Histochem Cytochem 46:1335–1337PubMed
18.
go back to reference Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W (2002) Analysis of vitamin D-receptor (VDR) and retinoic X-receptor α in breast cancer. Histochem J 34:35–40CrossRefPubMed Friedrich M, Axt-Fliedner R, Villena-Heinsen C, Tilgen W (2002) Analysis of vitamin D-receptor (VDR) and retinoic X-receptor α in breast cancer. Histochem J 34:35–40CrossRefPubMed
19.
go back to reference Friedrich M, Villena-Heinsen C, Tilgen W, Schmitd W, Reichrath J, Axt-Fliedner R (2002) Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res 22:1919–1924PubMed Friedrich M, Villena-Heinsen C, Tilgen W, Schmitd W, Reichrath J, Axt-Fliedner R (2002) Vitamin D receptor (VDR) expression is not a prognostic factor in breast cancer. Anticancer Res 22:1919–1924PubMed
20.
go back to reference Fukumoto S, Allan EH, Martin TJ (1994) Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. Biochem Biophys Acta 1201:223–228CrossRefPubMed Fukumoto S, Allan EH, Martin TJ (1994) Regulation of plasminogen activator inhibitor-1 (PAI-1) expression by 1,25-dihydroxyvitamin D-3 in normal and malignant rat osteoblasts. Biochem Biophys Acta 1201:223–228CrossRefPubMed
21.
go back to reference González-Sancho JM, Alvarez-Dolado M, Muñoz A (1998) 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expresión in mammary epithelial cells. FEBS Lett 426:225–228CrossRefPubMed González-Sancho JM, Alvarez-Dolado M, Muñoz A (1998) 1,25-Dihydroxyvitamin D3 inhibits tenascin-C expresión in mammary epithelial cells. FEBS Lett 426:225–228CrossRefPubMed
22.
go back to reference Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035–2040CrossRefPubMed Gross C, Stamey T, Hancock S, Feldman D (1998) Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol). J Urol 159:2035–2040CrossRefPubMed
23.
go back to reference Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M (1991) Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 110:27–32CrossRef Hildenbrand R, Glienke W, Magdolen V, Graeff H, Stutte HJ, Schmitt M (1991) Urokinase receptor localization in breast cancer and benign lesions assessed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 110:27–32CrossRef
24.
go back to reference Jankun J, Merrick HW, Goldblatt PJ (1993) Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53:135–144PubMed Jankun J, Merrick HW, Goldblatt PJ (1993) Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers. J Cell Biochem 53:135–144PubMed
25.
go back to reference Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001) Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370–1380PubMed Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J (2001) Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15:1370–1380PubMed
26.
go back to reference Jing Y, Xu XC, Lotan R, Waxman S, Mira-y-Lopes R (1996) Human breast carcinoma slice cultures retain retinoic acid sensitivity. Braz J Med Biol Res 29:1105–1108PubMed Jing Y, Xu XC, Lotan R, Waxman S, Mira-y-Lopes R (1996) Human breast carcinoma slice cultures retain retinoic acid sensitivity. Braz J Med Biol Res 29:1105–1108PubMed
27.
go back to reference Katayama MLH, Pasini FS, Folgueira MAAK, Snitcovsky IML, Brentani MM (2003) Molecular targets of 1,25(OH)2D3 in Hc11 normal mouse mammary cell line. J Steroid Biochem Mol Biol 84:57–69CrossRefPubMed Katayama MLH, Pasini FS, Folgueira MAAK, Snitcovsky IML, Brentani MM (2003) Molecular targets of 1,25(OH)2D3 in Hc11 normal mouse mammary cell line. J Steroid Biochem Mol Biol 84:57–69CrossRefPubMed
28.
go back to reference Kennedy S, Duffy MJ, Duggan C, Bernes C, Rafferty R, Kramer MD (1998) Semi-quantification of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Brit J Cancer 77:1638–1641PubMed Kennedy S, Duffy MJ, Duggan C, Bernes C, Rafferty R, Kramer MD (1998) Semi-quantification of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry. Brit J Cancer 77:1638–1641PubMed
29.
go back to reference Kole KL, Gyetko MR, Simpson RU, Sitrin RG (1991) Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. Biochem Pharmacol 41:585–591CrossRefPubMed Kole KL, Gyetko MR, Simpson RU, Sitrin RG (1991) Calcitriol-mediated modulation of urokinase-type plasminogen activator and plasminogen activator inhibitor-2. Biochem Pharmacol 41:585–591CrossRefPubMed
30.
go back to reference Koli K, Keski-Oja J (1993) Vitamin D3 and calcipotriol decrease extra cellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 101:706–712PubMed Koli K, Keski-Oja J (1993) Vitamin D3 and calcipotriol decrease extra cellular plasminogen activator activity in cultured keratinocytes. J Invest Dermatol 101:706–712PubMed
31.
go back to reference Koli K, Keski-Oja J (1996) Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblast cells relationships to plasminogen activation. J Invest Dermatol Symp Proc 1:33–38 Koli K, Keski-Oja J (1996) Vitamin D3 regulation of transforming growth factor-beta system in epithelial and fibroblast cells relationships to plasminogen activation. J Invest Dermatol Symp Proc 1:33–38
32.
go back to reference Koli K, Keski-Oja J (2000) 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion associated proteases in cultured malignant cells. Cell Growth Differ 11:221–229PubMed Koli K, Keski-Oja J (2000) 1α,25-dihydroxyvitamin D3 and its analogues down-regulate cell invasion associated proteases in cultured malignant cells. Cell Growth Differ 11:221–229PubMed
33.
go back to reference Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, Fisher J, Voorhees JJ (1999) 1,25-dihydroxyvitamin D3 increases nuclear vitamin D3 receptor by blocking ubiquitin/proteasome mediated degradation in human skin. Mol Endocrinol 13:1986–1994 Li XY, Boudjelal M, Xiao JH, Peng ZH, Asuru A, Kang S, Fisher J, Voorhees JJ (1999) 1,25-dihydroxyvitamin D3 increases nuclear vitamin D3 receptor by blocking ubiquitin/proteasome mediated degradation in human skin. Mol Endocrinol 13:1986–1994
34.
go back to reference Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Fred Sweep CGJ, Ulm K, Peyrat J-P, Martin P-M, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl P-O, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder E, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbihler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LVAM, Klijn JGM, O’Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Nat Cancer Inst 94:116–128CrossRefPubMed Look MP, van Putten WLJ, Duffy MJ, Harbeck N, Christensen IJ, Thomssen C, Kates R, Spyratos F, Fernö M, Eppenberger-Castori S, Fred Sweep CGJ, Ulm K, Peyrat J-P, Martin P-M, Magdelenat H, Brünner N, Duggan C, Lisboa BW, Bendahl P-O, Quillien V, Daver A, Ricolleau G, Meijer-van Gelder E, Manders P, Fiets WE, Blankenstein MA, Broët P, Romain S, Daxenbihler G, Windbichler G, Cufer T, Borstnar S, Kueng W, Beex LVAM, Klijn JGM, O’Higgins N, Eppenberger U, Jänicke F, Schmitt M, Foekens JA (2002) Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Nat Cancer Inst 94:116–128CrossRefPubMed
35.
go back to reference Mira-y-Lopes R, Osborne MP, Depalo AJ, Ossowski L (1991) Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer 47:827–832PubMed Mira-y-Lopes R, Osborne MP, Depalo AJ, Ossowski L (1991) Estradiol modulation of plasminogen activator production in organ cultures of human breast carcinomas: correlation with clinical outcome of anti-estrogen therapy. Int J Cancer 47:827–832PubMed
36.
go back to reference Mondino A, Resnati M, Blasi F (1999) Structure and function of the urokinase receptor. Thromb Haemost 82:19–22 Mondino A, Resnati M, Blasi F (1999) Structure and function of the urokinase receptor. Thromb Haemost 82:19–22
37.
go back to reference Mork-Hansen C, Frandsen TL, Brunner N, Binderup L (1994) 1α,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195–202PubMed Mork-Hansen C, Frandsen TL, Brunner N, Binderup L (1994) 1α,25-dihydroxyvitamin D3 inhibits the invasive potential of human breast cancer cells in vitro. Clin Exp Metastasis 12:195–202PubMed
38.
go back to reference Narvaez CJ, Zinser G, Welsh J (2001) Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 66:301–308CrossRefPubMed Narvaez CJ, Zinser G, Welsh J (2001) Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 66:301–308CrossRefPubMed
39.
go back to reference Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74:168–177PubMed Nielsen BS, Sehested M, Timshel S, Pyke C, Danø K (1996) Messenger RNA for urokinase plasminogen activator is expressed in myofibroblasts adjacent to cancer cells in human breast cancer. Lab Invest 74:168–177PubMed
40.
go back to reference Ree AH, Pacheco MM; Tvermyr M, Fodstad O, Brentani MM (2000) Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res 6:1778–1783PubMed Ree AH, Pacheco MM; Tvermyr M, Fodstad O, Brentani MM (2000) Expression of a novel factor, com1, in early tumor progression of breast cancer. Clin Cancer Res 6:1778–1783PubMed
41.
go back to reference Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727–732PubMed Schwartz GG, Wang MH, Zang M, Singh RK, Siegal GP (1997) 1 alpha,25-dihydroxyvitamin D (calcitriol) inhibits the invasiveness of human prostate cancer cells. Cancer Epidemiol Biomarkers Prev 6:727–732PubMed
42.
go back to reference Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22:205–222CrossRefPubMed Sidenius N, Blasi F (2003) The urokinase plasminogen activator system in cancer: recent advances and implication for prognosis and therapy. Cancer Metastasis Rev 22:205–222CrossRefPubMed
43.
go back to reference Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA (2002) Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts. Thromb Haemost 87:674–683PubMed Sieuwerts AM, Martens JW, Dorssers LC, Klijn JG, Foekens JA (2002) Differential effects of fibroblast growth factors on expression of genes of the plasminogen activator and insulin-like growth factor systems by human breast fibroblasts. Thromb Haemost 87:674–683PubMed
44.
go back to reference Stamps AC, Davies SC, Burman J, O’Hare MJ (1994) Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 57:865–874PubMed Stamps AC, Davies SC, Burman J, O’Hare MJ (1994) Analysis of proviral integration in human mammary epithelial cell lines immortalized by retroviral infection with a temperature-sensitive SV40 T-antigen construct. Int J Cancer 57:865–874PubMed
45.
go back to reference Uemeda T, Eguchi Y, Okino K, Kodama M, Hattori T (1997) Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183:388–397CrossRefPubMed Uemeda T, Eguchi Y, Okino K, Kodama M, Hattori T (1997) Cellular localization of urokinase-type plasminogen activator, its inhibitors, and their mRNAs in breast cancer tissues. J Pathol 183:388–397CrossRefPubMed
46.
go back to reference Yudoh K, Matsui H, Tsuji H (1997) Effects of 1,25-dihydroxyvitamin D3 on tumor cell invasion to the extracellular matrix in human fibrosarcoma HT1080 cells and its correlation with laminin. Tumor Biol 18:69–79 Yudoh K, Matsui H, Tsuji H (1997) Effects of 1,25-dihydroxyvitamin D3 on tumor cell invasion to the extracellular matrix in human fibrosarcoma HT1080 cells and its correlation with laminin. Tumor Biol 18:69–79
Metadata
Title
Vitamin D3 modulation of plasminogen activator inhibitor type-1 in human breast carcinomas under organ culture
Authors
Edson Mantovani Barbosa
Sueli Nonogaki
Maria Lucia Hirata Katayama
Maria Aparecida Azevedo Koike Folgueira
Venâncio Ferreira Avancini Alves
Maria Mitzi Brentani
Publication date
01-02-2004
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 2/2004
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-003-0929-5

Other articles of this Issue 2/2004

Virchows Archiv 2/2004 Go to the issue